Population-based and controlled study to evaluate neuroblastoma screening at one year of age in Germany: interim results.

Medical and pediatric oncology Pub Date : 2000-12-01 DOI:10.1002/1096-911x(20001201)35:6<701::aid-mpo47>3.0.co;2-s

F H Schilling, F Berthold, R Erttmann, J Michaelis, C Spix, J Sander, K Schwarz, J Treuner

{"title":"Population-based and controlled study to evaluate neuroblastoma screening at one year of age in Germany: interim results.","authors":"F H Schilling, F Berthold, R Erttmann, J Michaelis, C Spix, J Sander, K Schwarz, J Treuner","doi":"10.1002/1096-911x(20001201)35:6<701::aid-mpo47>3.0.co;2-s","DOIUrl":null,"url":null,"abstract":"Background: The German Neuroblastoma Screening Project is the first controlled and population-based screening study to evaluate the presumed benefit of neuroblastoma mass screening at 1 year of age (10-18 months).Procedure: Screening takes place in 6 of the 16 German states; children from the remainder serve as controls. The German Childhood Cancer Registry enables a mostly complete follow-up and detection of false-negative patients.Results: Up to December, 1999, 1,199,165 children were examined for urinary catecholamine metabolites and 124 cases of neuroblastoma were detected preclinically, giving a detection rate of 10.3/100,000. Within this cohort, 33 false-negative cases were found.Conclusions: The results of this screening program will be crucial for further implementation of neuroblastoma screening.","PeriodicalId":18531,"journal":{"name":"Medical and pediatric oncology","volume":"35 6","pages":"701-4"},"PeriodicalIF":0.0000,"publicationDate":"2000-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/1096-911x(20001201)35:6<701::aid-mpo47>3.0.co;2-s","citationCount":"11","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical and pediatric oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/1096-911x(20001201)35:6<701::aid-mpo47>3.0.co;2-s","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 11

Abstract

Background: The German Neuroblastoma Screening Project is the first controlled and population-based screening study to evaluate the presumed benefit of neuroblastoma mass screening at 1 year of age (10-18 months).

Procedure: Screening takes place in 6 of the 16 German states; children from the remainder serve as controls. The German Childhood Cancer Registry enables a mostly complete follow-up and detection of false-negative patients.

Results: Up to December, 1999, 1,199,165 children were examined for urinary catecholamine metabolites and 124 cases of neuroblastoma were detected preclinically, giving a detection rate of 10.3/100,000. Within this cohort, 33 false-negative cases were found.

Conclusions: The results of this screening program will be crucial for further implementation of neuroblastoma screening.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

以人群为基础的对照研究评估德国1岁时的神经母细胞瘤筛查:中期结果

背景:德国神经母细胞瘤筛查项目是第一个对照和基于人群的筛查研究，旨在评估1岁(10-18个月)神经母细胞瘤大规模筛查的预期益处。程序:筛选在德国16个州中的6个州进行;剩下的孩子作为对照组。德国儿童癌症登记处能够对假阴性患者进行基本完整的随访和检测。结果:截至1999年12月，共检查尿儿茶酚胺代谢物1199165例，临床前检出神经母细胞瘤124例，检出率为10.3/10万。在这个队列中，发现了33例假阴性病例。结论:该筛查项目的结果将对进一步实施神经母细胞瘤筛查至关重要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Medical and pediatric oncology

自引率

0.00%

发文量

期刊最新文献

Palliative Care in Pediatric Oncology Treatment Decision Making Conclusion and Future Perspective Exercise and Physical Activity Complications of Therapy